guest ::
| Home > Publications Database > Sirtuin 2 Inhibition Improves Cognitive Performance and Acts on Amyloid-β Protein Precursor Processing in Two Alzheimer's Disease Mouse Models. > print |
| Home > Publications Database > Sirtuin 2 Inhibition Improves Cognitive Performance and Acts on Amyloid-β Protein Precursor Processing in Two Alzheimer's Disease Mouse Models. > print |
| 001 | 138753 | ||
| 005 | 20240321220507.0 | ||
| 024 | 7 | _ | |a 10.3233/JAD-151135 |2 doi |
| 024 | 7 | _ | |a pmid:27372638 |2 pmid |
| 024 | 7 | _ | |a 1387-2877 |2 ISSN |
| 024 | 7 | _ | |a 1875-8908 |2 ISSN |
| 024 | 7 | _ | |a altmetric:9543235 |2 altmetric |
| 037 | _ | _ | |a DZNE-2020-05075 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Biella, Gloria |b 0 |
| 245 | _ | _ | |a Sirtuin 2 Inhibition Improves Cognitive Performance and Acts on Amyloid-β Protein Precursor Processing in Two Alzheimer's Disease Mouse Models. |
| 260 | _ | _ | |a Amsterdam |c 2016 |b IOS Press |
| 264 | _ | 1 | |3 print |2 Crossref |b IOS Press |c 2016-08-03 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1710940731_2065 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The neuropathological hallmarks of Alzheimer's disease (AD) are extracellular plaques built up by the accumulation of the amyloid-β protein precursor (AβPP)-derived peptide β (Aβ), and intracellular tangles of hyperphosphorylated tau protein. Sirtuin 2 (SIRT2) is a member of the sirtuin family, featuring conserved enzymes with deacetylase activity and involved in several cell molecular pathways. We investigated the importance of SIRT2 inhibition in AD. We inhibited SIRT2 by small molecules (AGK-2, AK-7) and examined AβPP metabolism in H4-SW neuroglioma cells overexpressing AβPP and two AD transgenic mouse models (3xTg-AD and APP23). The in vitro studies suggested that the inhibition of SIRT2 reduced Aβ production; in vivo data showed an improvement of cognitive performance in the novel object recognition test, and an effect on AβPP proteolytic processing leading to a reduction of soluble β-AβPP and an increase of soluble α-AβPP protein. In 3xTg-AD mice, we noticed that total tau protein level rose. Overall, our pre-clinical data support a role for SIRT2 inhibition in the improvement of cognitive performance and the modulation of molecular mechanisms relevant for AD, thus deserving attention as possible therapeutic strategy. |
| 536 | _ | _ | |a 342 - Disease Mechanisms and Model Systems (POF3-342) |0 G:(DE-HGF)POF3-342 |c POF3-342 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a 3-(1-azepanylsulfonyl)-N-(3-bromphenyl)benzamide |2 NLM Chemicals |
| 650 | _ | 7 | |a AGK2 compound |2 NLM Chemicals |
| 650 | _ | 7 | |a Aif1 protein, mouse |2 NLM Chemicals |
| 650 | _ | 7 | |a Amyloid beta-Peptides |2 NLM Chemicals |
| 650 | _ | 7 | |a Amyloid beta-Protein Precursor |2 NLM Chemicals |
| 650 | _ | 7 | |a Benzamides |2 NLM Chemicals |
| 650 | _ | 7 | |a Calcium-Binding Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Enzyme Inhibitors |2 NLM Chemicals |
| 650 | _ | 7 | |a Furans |2 NLM Chemicals |
| 650 | _ | 7 | |a Glial Fibrillary Acidic Protein |2 NLM Chemicals |
| 650 | _ | 7 | |a Microfilament Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Peptide Fragments |2 NLM Chemicals |
| 650 | _ | 7 | |a Quinolines |2 NLM Chemicals |
| 650 | _ | 7 | |a Sulfonamides |2 NLM Chemicals |
| 650 | _ | 7 | |a amyloid beta-protein (1-40) |2 NLM Chemicals |
| 650 | _ | 7 | |a amyloid beta-protein (1-42) |2 NLM Chemicals |
| 650 | _ | 7 | |a Sirtuin 2 |0 EC 3.5.1.- |2 NLM Chemicals |
| 650 | _ | 2 | |a Alzheimer Disease: complications |2 MeSH |
| 650 | _ | 2 | |a Alzheimer Disease: genetics |2 MeSH |
| 650 | _ | 2 | |a Alzheimer Disease: pathology |2 MeSH |
| 650 | _ | 2 | |a Amyloid beta-Peptides: metabolism |2 MeSH |
| 650 | _ | 2 | |a Amyloid beta-Protein Precursor: genetics |2 MeSH |
| 650 | _ | 2 | |a Amyloid beta-Protein Precursor: metabolism |2 MeSH |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Benzamides: pharmacology |2 MeSH |
| 650 | _ | 2 | |a Benzamides: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Brain: drug effects |2 MeSH |
| 650 | _ | 2 | |a Brain: metabolism |2 MeSH |
| 650 | _ | 2 | |a Calcium-Binding Proteins: metabolism |2 MeSH |
| 650 | _ | 2 | |a Cell Line, Tumor |2 MeSH |
| 650 | _ | 2 | |a Cognition Disorders: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Cognition Disorders: etiology |2 MeSH |
| 650 | _ | 2 | |a Cognition Disorders: metabolism |2 MeSH |
| 650 | _ | 2 | |a Cognition Disorders: pathology |2 MeSH |
| 650 | _ | 2 | |a Disease Models, Animal |2 MeSH |
| 650 | _ | 2 | |a Enzyme Inhibitors: pharmacology |2 MeSH |
| 650 | _ | 2 | |a Enzyme Inhibitors: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Furans: pharmacology |2 MeSH |
| 650 | _ | 2 | |a Furans: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Gene Expression Regulation: drug effects |2 MeSH |
| 650 | _ | 2 | |a Gene Expression Regulation: genetics |2 MeSH |
| 650 | _ | 2 | |a Glial Fibrillary Acidic Protein: metabolism |2 MeSH |
| 650 | _ | 2 | |a Glioma: pathology |2 MeSH |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 650 | _ | 2 | |a Mice, Inbred C57BL |2 MeSH |
| 650 | _ | 2 | |a Mice, Transgenic |2 MeSH |
| 650 | _ | 2 | |a Microfilament Proteins: metabolism |2 MeSH |
| 650 | _ | 2 | |a Peptide Fragments: metabolism |2 MeSH |
| 650 | _ | 2 | |a Phosphorylation: drug effects |2 MeSH |
| 650 | _ | 2 | |a Quinolines: pharmacology |2 MeSH |
| 650 | _ | 2 | |a Quinolines: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Sirtuin 2: metabolism |2 MeSH |
| 650 | _ | 2 | |a Sulfonamides: pharmacology |2 MeSH |
| 650 | _ | 2 | |a Sulfonamides: therapeutic use |2 MeSH |
| 700 | 1 | _ | |a Fusco, Federica |b 1 |
| 700 | 1 | _ | |a Nardo, Emanuele |b 2 |
| 700 | 1 | _ | |a Bernocchi, Ottavia |b 3 |
| 700 | 1 | _ | |a Colombo, Alessio |0 P:(DE-2719)2340744 |b 4 |u dzne |
| 700 | 1 | _ | |a Lichtenthaler, Stefan F |0 P:(DE-2719)2181459 |b 5 |u dzne |
| 700 | 1 | _ | |a Forloni, Gianluigi |b 6 |
| 700 | 1 | _ | |a Albani, Diego |0 P:(DE-HGF)0 |b 7 |e Corresponding author |
| 773 | 1 | 8 | |a 10.3233/jad-151135 |b : IOS Press, 2016-08-03 |n 3 |p 1193-1207 |3 journal-article |2 Crossref |t Journal of Alzheimer's Disease |v 53 |y 2016 |x 1387-2877 |
| 773 | _ | _ | |a 10.3233/JAD-151135 |g Vol. 53, no. 3, p. 1193 - 1207 |0 PERI:(DE-600)2070772-1 |n 3 |q 53:3<1193 - 1207 |p 1193-1207 |t Journal of Alzheimer's disease |v 53 |y 2016 |x 1387-2877 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/138753/files/DZNE-2020-05075_Restricted.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/138753/files/DZNE-2020-05075_Restricted.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:pub.dzne.de:138753 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 4 |6 P:(DE-2719)2340744 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2181459 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-342 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Disease Mechanisms and Model Systems |x 0 |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J ALZHEIMERS DIS : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-2719)1110006 |k AG Lichtenthaler |l Neuroproteomics |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1110006 |
| 980 | _ | _ | |a UNRESTRICTED |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/00002093-200210000-00001 |2 Crossref |o 10.1097/00002093-200210000-00001 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/S0197-4580(01)00307-4 |2 Crossref |o 10.1016/S0197-4580(01)00307-4 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/01.wad.0000213866.86934.7e |2 Crossref |o 10.1097/01.wad.0000213866.86934.7e |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1038/sj.emboj.7600061 |2 Crossref |o 10.1038/sj.emboj.7600061 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1126/science.1691865 |2 Crossref |o 10.1126/science.1691865 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1126/science.2111583 |2 Crossref |o 10.1126/science.2111583 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/0014-5793(94)80260-2 |2 Crossref |o 10.1016/0014-5793(94)80260-2 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/0166-2236(93)90078-Z |2 Crossref |o 10.1016/0166-2236(93)90078-Z |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/0197-4580(89)90076-6 |2 Crossref |o 10.1016/0197-4580(89)90076-6 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/0959-4388(91)90067-H |2 Crossref |o 10.1016/0959-4388(91)90067-H |
| 999 | C | 5 | |y 2010 |2 Crossref |o Polito 2010 |
| 999 | C | 5 | |y 2012 |2 Crossref |o Donmez 2012 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1371/journal.pone.0116919 |2 Crossref |o 10.1371/journal.pone.0116919 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1073/pnas.1002924107 |2 Crossref |o 10.1073/pnas.1002924107 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1126/science.1143780 |2 Crossref |o 10.1126/science.1143780 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.celrep.2012.11.001 |2 Crossref |o 10.1016/j.celrep.2012.11.001 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1021/cb100376q |2 Crossref |o 10.1021/cb100376q |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.3233/JAD-131430 |2 Crossref |o 10.3233/JAD-131430 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/S0896-6273(03)00434-3 |2 Crossref |o 10.1016/S0896-6273(03)00434-3 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.nbd.2012.08.011 |2 Crossref |o 10.1016/j.nbd.2012.08.011 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.phrs.2006.12.010 |2 Crossref |o 10.1016/j.phrs.2006.12.010 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.3233/JAD-142994 |2 Crossref |o 10.3233/JAD-142994 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1159/000356430 |2 Crossref |o 10.1159/000356430 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1038/emboj.2010.167 |2 Crossref |o 10.1038/emboj.2010.167 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1111/j.1471-4159.1992.tb09754.x |2 Crossref |o 10.1111/j.1471-4159.1992.tb09754.x |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1186/1742-2094-2-23 |2 Crossref |o 10.1186/1742-2094-2-23 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1186/1471-2202-9-81 |2 Crossref |o 10.1186/1471-2202-9-81 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1073/pnas.1314145110 |2 Crossref |o 10.1073/pnas.1314145110 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.neuron.2010.08.044 |2 Crossref |o 10.1016/j.neuron.2010.08.044 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.jalz.2012.02.003 |2 Crossref |o 10.1016/j.jalz.2012.02.003 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1007/s12017-014-8291-0 |2 Crossref |o 10.1007/s12017-014-8291-0 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1111/j.1749-6632.2000.tb06915.x |2 Crossref |o 10.1111/j.1749-6632.2000.tb06915.x |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.neuron.2014.10.038 |2 Crossref |o 10.1016/j.neuron.2014.10.038 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1523/JNEUROSCI.0284-14.2014 |2 Crossref |o 10.1523/JNEUROSCI.0284-14.2014 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1523/JNEUROSCI.3203-08.2008 |2 Crossref |o 10.1523/JNEUROSCI.3203-08.2008 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.neurobiolaging.2012.11.020 |2 Crossref |o 10.1016/j.neurobiolaging.2012.11.020 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1152/physrev.00023.2009 |2 Crossref |o 10.1152/physrev.00023.2009 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1074/jbc.M507892200 |2 Crossref |o 10.1074/jbc.M507892200 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1001/archneur.1997.00550170111022 |2 Crossref |o 10.1001/archneur.1997.00550170111022 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.nbd.2008.04.011 |2 Crossref |o 10.1016/j.nbd.2008.04.011 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1111/j.1471-4159.2011.07637.x |2 Crossref |o 10.1111/j.1471-4159.2011.07637.x |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1007/s00401-014-1347-2 |2 Crossref |o 10.1007/s00401-014-1347-2 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.3233/JAD-1999-14-512 |2 Crossref |o 10.3233/JAD-1999-14-512 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1002/cm.970080309 |2 Crossref |o 10.1002/cm.970080309 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1097/00005072-199609000-00003 |2 Crossref |o 10.1097/00005072-199609000-00003 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.3389/fphar.2014.00089 |2 Crossref |o 10.3389/fphar.2014.00089 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1016/j.expneurol.2009.10.013 |2 Crossref |o 10.1016/j.expneurol.2009.10.013 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|